Mucoadhesive Nanosystems for Nose-to-Brain Drug Delivery in the Treatment of Central Nervous System Diseases

Bors, L.A.; Erdö, F. Overcoming the blood-brain barrier challenges and tricks for CNS drug delivery. Sci. Pharm., 2019, 87(1), 6.
[http://dx.doi.org/10.3390/scipharm87010006]

Neurological Disorders. Public Health Challenges; Geneva, 2006.

Kumar, K.; Sharma, S.; Kumar, P.; Deshmukh, R. Therapeutic potential of GABAB receptor ligands in drug addiction, anxiety, depression and other CNS disorders. Pharmacol. Biochem. Behav., 2013, 174-184.
[http://dx.doi.org/10.1016/j.pbb.2013.07.003] [PMID: 23872369]

Daigre, C.; Roncero, C.; Grau-López, L.; Martínez-Luna, N.; Prat, G.; Valero, S.; Tejedor, R.; Ramos-Quiroga, J.A.; Casas, M. Attention deficit hyperactivity disorder in cocaine-dependent adults: A psychiatric comorbidity analysis. Am. J. Addict., 2013, 22(5), 466-473.
[http://dx.doi.org/10.1111/j.1521-0391.2013.12047.x] [PMID: 23952892]

Naeem, S.; Najam, R.; Khan, S.S.; Mirza, T.; Sikandar, B. Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats. Metab. Brain Dis., 2019, 34(4), 1191-1199.
[http://dx.doi.org/10.1007/s11011-019-00416-1] [PMID: 31055785]

Thijs, R.D.; Surges, R.; O’Brien, T.J.; Sander, J.W. Epilepsy in adults. The Lancet, 2019, 689-701.
[http://dx.doi.org/10.1016/S0140-6736(18)32596-0]

Tamil Selvan, S.; Padmanabhan, P.; Zoltán Gulyás, B. Nanotechnology-based diagnostics and therapy for pathogen-related infections in the CNS. ACS Chem. Neurosci., 2020, 11(16), 2371-2377.
[http://dx.doi.org/10.1021/acschemneuro.9b00470] [PMID: 31726008]

Lee, B.J.; Vu, B.N.; Seddon, A.N.; Hodgson, H.A.; Wang, S.K. Treatment considerations for CNS infections caused by vancomycin-resistant Enterococcus Faecium: A focused review of linezolid and daptomycin. Ann. Pharmacother., 2020, 54(12), 1243-1251.
[http://dx.doi.org/10.1177/1060028020932513] [PMID: 32506921]

Nozuma, S.; Jacobson, S. Neuroimmunology of human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. Front. Microbiol., 2019, 10, 885.
[http://dx.doi.org/10.3389/fmicb.2019.00885] [PMID: 31105674]

Dobson, R.; Giovannoni, G. Multiple sclerosis - a review. Eur. J. Neurol., 2019, 26(1), 27-40.
[http://dx.doi.org/10.1111/ene.13819] [PMID: 30300457]

Tan, C.H.; Bonham, L.W.; Fan, C.C.; Mormino, E.C.; Sugrue, L.P.; Broce, I.J.; Hess, C.P.; Yokoyama, J.S.; Rabinovici, G.D.; Miller, B.L.; Yaffe, K.; Schellenberg, G.D.; Kauppi, K.; Holland, D.; McEvoy, L.K.; Kukull, W.A.; Tosun, D.; Weiner, M.W.; Sperling, R.A.; Bennett, D.A.; Hyman, B.T.; Andreassen, O.A.; Dale, A.M.; Desikan, R.S. Polygenic hazard score, amyloid deposition and Alzheimer’s neurodegeneration. Brain, 2019, 142(2), 460-470.
[http://dx.doi.org/10.1093/brain/awy327] [PMID: 30689776]

di Domenico, A.; Carola, G.; Calatayud, C.; Pons-Espinal, M.; Muñoz, J.P.; Richaud-Patin, Y.; Fernandez-Carasa, I.; Gut, M.; Faella, A.; Parameswaran, J.; Soriano, J.; Ferrer, I.; Tolosa, E.; Zorzano, A.; Cuervo, A.M.; Raya, A.; Consiglio, A. Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson’s Disease. Stem Cell Reports, 2019, 12(2), 213-229.
[http://dx.doi.org/10.1016/j.stemcr.2018.12.011] [PMID: 30639209]

Morton, A.J.; Middleton, B.; Rudiger, S.; Bawden, C.S.; Kuchel, T.R.; Skene, D.J. Increased plasma melatonin in presymptomatic huntington disease sheep (ovis aries): Compensatory neuroprotection in a neurodegenerative disease? J. Pineal Res., 2020, 68(2), e12624.
[http://dx.doi.org/10.1111/jpi.12624] [PMID: 31742766]

Cecchelli, R.; Berezowski, V.; Lundquist, S.; Culot, M.; Renftel, M.; Dehouck, M.P.; Fenart, L. Modelling of the blood - brain barrier in drug discovery and development. Nat. Rev. Drug Discov., 2007, 650-661.
[http://dx.doi.org/10.1038/nrd2368]

Kuhnline Sloan, C.D.; Nandi, P.; Linz, T.H.; Aldrich, J.V.; Audus, K.L.; Lunte, S.M. Analytical and biological methods for probing the blood-brain barrier. Annu. Rev. Anal. Chem. (Palo Alto, Calif.), 2012, 5(1), 505-531.
[http://dx.doi.org/10.1146/annurev-anchem-062011-143002] [PMID: 22708905]

Merkus, P.; Guchelaar, H.J.; Bosch, D.A.; Merkus, F.W.H.M. Direct access of drugs to the human brain after intranasal drug administration? Neurology, 2003, 60(10), 1669-1671.
[http://dx.doi.org/10.1212/01.WNL.0000067993.60735.77] [PMID: 12771261]

Lawrence, R.N. William pardridge discusses the lack of BBB research. Drug Discov. Today, 2002, 223-226.
[http://dx.doi.org/10.1016/S1359-6446(02)02195-5]

Chen, Y.; Dalwadi, G.; Benson, H.A. Drug delivery across the blood-brain barrier. Curr. Drug Deliv., 2004, 1(4), 361-376.
[http://dx.doi.org/10.2174/1567201043334542] [PMID: 16305398]

Graff, C.L.; Pollack, G.M. Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci., 2005, 1187-1195.
[http://dx.doi.org/10.1002/jps.20318]

Amorim, C. de M. Desenvolvimento de sistemas de liberação nanoestruturados mucoadesivos contendo o ácido elágico visando o tratamento da doença de Alzheimer., Available at: https://repositorio.ufsc.br/handle/123456789/129682

Gänger, S.; Schindowski, K. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics, 2018, 10(3), 116.
[http://dx.doi.org/10.3390/pharmaceutics10030116]

Costantino, H.R.; Illum, L.; Brandt, G.; Johnson, P.H.; Quay, S.C. Intranasal delivery: Physicochemical and therapeutic aspects. Int. J. Pharm., 2007, 337(1-2), 1-24.
[http://dx.doi.org/10.1016/j.ijpharm.2007.03.025] [PMID: 17475423]

Heinemann, L. New ways of insulin delivery. Int. J. Clin. Pract. Suppl., 2011, (170), 31-46.
[http://dx.doi.org/10.1111/j.1742-1241.2010.02577.x] [PMID: 21323811]

Tong, Un. Nasal administration of quercetin liposomes modulate cognitive impairment and inhibit acetylcholinesterase activity in hippocampus. Am. J. Neurosci., 2010, 1(1), 21-27.
[http://dx.doi.org/10.3844/ajnsp.2010.21.27]

Ugwoke, M.I.; Agu, R.U.; Verbeke, N.; Kinget, R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev., 2005, 57(11), 1640-1665.
[http://dx.doi.org/10.1016/j.addr.2005.07.009] [PMID: 16182408]

Pardeshi, C.V.; Belgamwar, V.S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting. Expert Opin. Drug Deliv., 2013, 10(7), 957-972.
[http://dx.doi.org/10.1517/17425247.2013.790887] [PMID: 23586809]

de Araújo, P.R.; Calixto, G.M.F.; da Silva, I.C.; de Paula Zago, L.H.; Oshiro, Junior J.A.; Pavan, F.R.; Ribeiro, A.O.; Fontana, C.R.; Chorilli, M. Mucoadhesive in situ gelling liquid crystalline precursor system to improve the vaginal administration of drugs. AAPS PharmSciTech, 2019, 20(6), 225.
[http://dx.doi.org/10.1208/s12249-019-1439-3] [PMID: 31214798]

Gan, L.; Cookson, M.R.; Petrucelli, L.; La Spada, A.R. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat. Neurosci., 2018, 21(10), 1300-1309.
[http://dx.doi.org/10.1038/s41593-018-0237-7] [PMID: 30258237]

Piccardo, P.; Asher, D.M. Complex proteinopathies and neurodegeneration: Insights from the study of transmissible spongiform encephalopathies. Arq. Neuropsiquiatr., 2018, 76(10), 705-712.
[http://dx.doi.org/10.1590/0004-282x20180111] [PMID: 30427511]

Bates, G.P.; Dorsey, R.; Gusella, J.F.; Hayden, M.R.; Kay, C.; Leavitt, B.R.; Nance, M.; Ross, C.A.; Scahill, R.I.; Wetzel, R.; Wild, E.J.; Tabrizi, S.J. Huntington disease. Nat. Rev. Dis. Primers, 2015, 1(1), 15005.
[http://dx.doi.org/10.1038/nrdp.2015.5] [PMID: 27188817]

Groen, E.J.N.; Talbot, K.; Gillingwater, T.H. Advances in therapy for spinal muscular atrophy: Promises and challenges. Nat. Rev. Neurol., 2018, 14(4), 214-224.
[http://dx.doi.org/10.1038/nrneurol.2018.4] [PMID: 29422644]

Dugger, B.N.; Dickson, D.W. Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol., 2017, 9(7), a028035.
[http://dx.doi.org/10.1101/cshperspect.a028035] [PMID: 28062563]

Katsuno, M.; Sahashi, K.; Iguchi, Y.; Hashizume, A. Preclinical progression of neurodegenerative diseases. Nagoya J. Med. Sci., 2018, 80(3), 289-298.
[http://dx.doi.org/10.18999/nagjms.80.3.289] [PMID: 30214078]

Levenson, R.W.; Sturm, V.E.; Haase, C.M. Emotional and behavioral symptoms in neurodegenerative disease: A model for studying the neural bases of psychopathology. Annu. Rev. Clin. Psychol., 2014, 10, 581-606.
[http://dx.doi.org/10.1146/annurev-clinpsy-032813-153653] [PMID: 24437433]

Klockgether, T.; Mariotti, C.; Paulson, H.L. Spinocerebellar ataxia. Nat. Rev. Dis. Primers, 2019, 5(1), 24.
[http://dx.doi.org/10.1038/s41572-019-0074-3] [PMID: 30975995]

Sullivan, R.; Yau, W.Y.; O’Connor, E.; Houlden, H. Spinocerebellar ataxia: An update. J. Neurol., 2019, 266(2), 533-544.
[http://dx.doi.org/10.1007/s00415-018-9076-4] [PMID: 30284037]

Nichols, M.J.; Newsome, W.T. The neurobiology of cognition. Nature, 1999, 402(6761)(Suppl.), C35-C38.
[http://dx.doi.org/10.1038/35011531] [PMID: 10591223]

Trojsi, F.; Christidi, F.; Migliaccio, R.; Santamaría-García, H.; Santangelo, G. Behavioural and cognitive changes in neurodegenerative diseases and brain injury. Behav. Neurol., 2018, 2018, 4935915.
[http://dx.doi.org/10.1155/2018/4935915] [PMID: 30147810]

Arnaoutoglou, N.A.; O’Brien, J.T.; Underwood, B.R. Dementia with Lewy bodies - from scientific knowledge to clinical insights. Nat. Rev. Neurol., 2019, 15(2), 103-112.
[http://dx.doi.org/10.1038/s41582-018-0107-7] [PMID: 30559465]

Elahi, F.M.; Miller, B.L. A clinicopathological approach to the diagnosis of dementia. Nat. Rev. Neurol., 2017, 13(8), 457-476.
[http://dx.doi.org/10.1038/nrneurol.2017.96] [PMID: 28708131]

Hinz, F.I.; Geschwind, D.H. Molecular genetics of neurodegenerative dementias. Cold Spring Harb. Perspect. Biol., 2017, 9(4), a023705.
[http://dx.doi.org/10.1101/cshperspect.a023705] [PMID: 27940516]

Feigin, V.L.; Vos, T.; Nichols, E.; Owolabi, M.O.; Carroll, W.M.; Dichgans, M.; Deuschl, G.; Parmar, P.; Brainin, M.; Murray, C. The global burden of neurological disorders: Translating evidence into policy. Lancet Neurol., 2020, 19(3), 255-265.
[http://dx.doi.org/10.1016/S1474-4422(19)30411-9] [PMID: 31813850]

Feigin, V.L.; Nichols, E.; Alam, T.; Bannick, M.S.; Beghi, E.; Blake, N.; Culpepper, W.J.; Dorsey, E.R.; Elbaz, A.; Ellenbogen, R.G. Global, regional, and national burden of neurological disorders, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 2019, 18(5), 459-480.
[http://dx.doi.org/10.1016/S1474-4422(18)30499-X] [PMID: 30879893]

Murray, C.J.L.; Vos, T.; Lozano, R.; Naghavi, M.; Flaxman, A.D.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.A.; Abdalla, S.; Aboyans, V.; Abraham, J.; Ackerman, I.; Aggarwal, R.; Ahn, S.Y.; Ali, M.K.; Alvarado, M.; Anderson, H.R.; Anderson, L.M.; Andrews, K.G.; Atkinson, C.; Baddour, L.M.; Bahalim, A.N.; Barker-Collo, S.; Barrero, L.H.; Bartels, D.H.; Basáñez, M.G.; Baxter, A.; Bell, M.L.; Benjamin, E.J.; Bennett, D.; Bernabé, E.; Bhalla, K.; Bhandari, B.; Bikbov, B.; Bin Abdulhak, A.; Birbeck, G.; Black, J.A.; Blencowe, H.; Blore, J.D.; Blyth, F.; Bolliger, I.; Bonaventure, A.; Boufous, S.; Bourne, R.; Boussinesq, M.; Braithwaite, T.; Brayne, C.; Bridgett, L.; Brooker, S.; Brooks, P.; Brugha, T.S.; Bryan-Hancock, C.; Bucello, C.; Buchbinder, R.; Buckle, G.; Budke, C.M.; Burch, M.; Burney, P.; Burstein, R.; Calabria, B.; Campbell, B.; Canter, C.E.; Carabin, H.; Carapetis, J.; Carmona, L.; Cella, C.; Charlson, F.; Chen, H.; Cheng, A.T.; Chou, D.; Chugh, S.S.; Coffeng, L.E.; Colan, S.D.; Colquhoun, S.; Colson, K.E.; Condon, J.; Connor, M.D.; Cooper, L.T.; Corriere, M.; Cortinovis, M.; de Vaccaro, K.C.; Couser, W.; Cowie, B.C.; Criqui, M.H.; Cross, M.; Dabhadkar, K.C.; Dahiya, M.; Dahodwala, N.; Damsere-Derry, J.; Danaei, G.; Davis, A.; De Leo, D.; Degenhardt, L.; Dellavalle, R.; Delossantos, A.; Denenberg, J.; Derrett, S.; Des Jarlais, D.C.; Dharmaratne, S.D.; Dherani, M.; Diaz-Torne, C.; Dolk, H.; Dorsey, E.R.; Driscoll, T.; Duber, H.; Ebel, B.; Edmond, K.; Elbaz, A.; Ali, S.E.; Erskine, H.; Erwin, P.J.; Espindola, P.; Ewoigbokhan, S.E.; Farzadfar, F.; Feigin, V.; Felson, D.T.; Ferrari, A.; Ferri, C.P.; Fèvre, E.M.; Finucane, M.M.; Flaxman, S.; Flood, L.; Foreman, K.; Forouzanfar, M.H.; Fowkes, F.G.; Fransen, M.; Freeman, M.K.; Gabbe, B.J.; Gabriel, S.E.; Gakidou, E.; Ganatra, H.A.; Garcia, B.; Gaspari, F.; Gillum, R.F.; Gmel, G.; Gonzalez-Medina, D.; Gosselin, R.; Grainger, R.; Grant, B.; Groeger, J.; Guillemin, F.; Gunnell, D.; Gupta, R.; Haagsma, J.; Hagan, H.; Halasa, Y.A.; Hall, W.; Haring, D.; Haro, J.M.; Harrison, J.E.; Havmoeller, R.; Hay, R.J.; Higashi, H.; Hill, C.; Hoen, B.; Hoffman, H.; Hotez, P.J.; Hoy, D.; Huang, J.J.; Ibeanusi, S.E.; Jacobsen, K.H.; James, S.L.; Jarvis, D.; Jasrasaria, R.; Jayaraman, S.; Johns, N.; Jonas, J.B.; Karthikeyan, G.; Kassebaum, N.; Kawakami, N.; Keren, A.; Khoo, J.P.; King, C.H.; Knowlton, L.M.; Kobusingye, O.; Koranteng, A.; Krishnamurthi, R.; Laden, F.; Lalloo, R.; Laslett, L.L.; Lathlean, T.; Leasher, J.L.; Lee, Y.Y.; Leigh, J.; Levinson, D.; Lim, S.S.; Limb, E.; Lin, J.K.; Lipnick, M.; Lipshultz, S.E.; Liu, W.; Loane, M.; Ohno, S.L.; Lyons, R.; Mabweijano, J.; MacIntyre, M.F.; Malekzadeh, R.; Mallinger, L.; Manivannan, S.; Marcenes, W.; March, L.; Margolis, D.J.; Marks, G.B.; Marks, R.; Matsumori, A.; Matzopoulos, R.; Mayosi, B.M.; McAnulty, J.H.; McDermott, M.M.; McGill, N.; McGrath, J.; Medina-Mora, M.E.; Meltzer, M.; Mensah, G.A.; Merriman, T.R.; Meyer, A.C.; Miglioli, V.; Miller, M.; Miller, T.R.; Mitchell, P.B.; Mock, C.; Mocumbi, A.O.; Moffitt, T.E.; Mokdad, A.A.; Monasta, L.; Montico, M.; Moradi-Lakeh, M.; Moran, A.; Morawska, L.; Mori, R.; Murdoch, M.E.; Mwaniki, M.K.; Naidoo, K.; Nair, M.N.; Naldi, L.; Narayan, K.M.; Nelson, P.K.; Nelson, R.G.; Nevitt, M.C.; Newton, C.R.; Nolte, S.; Norman, P.; Norman, R.; O’Donnell, M.; O’Hanlon, S.; Olives, C.; Omer, S.B.; Ortblad, K.; Osborne, R.; Ozgediz, D.; Page, A.; Pahari, B.; Pandian, J.D.; Rivero, A.P.; Patten, S.B.; Pearce, N.; Padilla, R.P.; Perez-Ruiz, F.; Perico, N.; Pesudovs, K.; Phillips, D.; Phillips, M.R.; Pierce, K.; Pion, S.; Polanczyk, G.V.; Polinder, S.; Pope, C.A., III; Popova, S.; Porrini, E.; Pourmalek, F.; Prince, M.; Pullan, R.L.; Ramaiah, K.D.; Ranganathan, D.; Razavi, H.; Regan, M.; Rehm, J.T.; Rein, D.B.; Remuzzi, G.; Richardson, K.; Rivara, F.P.; Roberts, T.; Robinson, C.; De Leòn, F.R.; Ronfani, L.; Room, R.; Rosenfeld, L.C.; Rushton, L.; Sacco, R.L.; Saha, S.; Sampson, U.; Sanchez-Riera, L.; Sanman, E.; Schwebel, D.C.; Scott, J.G.; Segui-Gomez, M.; Shahraz, S.; Shepard, D.S.; Shin, H.; Shivakoti, R.; Singh, D.; Singh, G.M.; Singh, J.A.; Singleton, J.; Sleet, D.A.; Sliwa, K.; Smith, E.; Smith, J.L.; Stapelberg, N.J.; Steer, A.; Steiner, T.; Stolk, W.A.; Stovner, L.J.; Sudfeld, C.; Syed, S.; Tamburlini, G.; Tavakkoli, M.; Taylor, H.R.; Taylor, J.A.; Taylor, W.J.; Thomas, B.; Thomson, W.M.; Thurston, G.D.; Tleyjeh, I.M.; Tonelli, M.; Towbin, J.A.; Truelsen, T.; Tsilimbaris, M.K.; Ubeda, C.; Undurraga, E.A.; van der Werf, M.J.; van Os, J.; Vavilala, M.S.; Venketasubramanian, N.; Wang, M.; Wang, W.; Watt, K.; Weatherall, D.J.; Weinstock, M.A.; Weintraub, R.; Weisskopf, M.G.; Weissman, M.M.; White, R.A.; Whiteford, H.; Wiebe, N.; Wiersma, S.T.; Wilkinson, J.D.; Williams, H.C.; Williams, S.R.; Witt, E.; Wolfe, F.; Woolf, A.D.; Wulf, S.; Yeh, P.H.; Zaidi, A.K.; Zheng, Z.J.; Zonies, D.; Lopez, A.D.; AlMazroa, M.A.; Memish, Z.A. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet, 2012, 380(9859), 2197-2223.
[http://dx.doi.org/10.1016/S0140-6736(12)61689-4] [PMID: 23245608]

Shubhakaran, K.P.; Chin, J.H. The global burden of neurologic diseases. Neurology, 2015, 84(7), 758.
[http://dx.doi.org/10.1212/WNL.0000000000001251] [PMID: 25688151]

Association, A. 2020 Alzheimer’s Disease Facts and Figures, 2020.

Marras, C.; Beck, J.C.; Bower, J.H.; Roberts, E.; Ritz, B.; Ross, G.W.; Abbott, R.D.; Savica, R.; Van Den Eeden, S.K.; Willis, A.W.; Tanner, C.M. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis., 2018, 4(1), 21.
[http://dx.doi.org/10.1038/s41531-018-0058-0] [PMID: 30003140]

Mehta, P.; Kaye, W.; Raymond, J.; Punjani, R.; Larson, T.; Cohen, J.; Muravov, O.; Horton, K. Prevalence of amyotrophic lateral sclerosis - United States, 2015. MMWR Morb. Mortal. Wkly. Rep., 2018, 67(46), 1285-1289.
[http://dx.doi.org/10.15585/mmwr.mm6746a1] [PMID: 30462626]

Burns, A.; Iliffe, S. Alzheimer’s disease. BMJ, 2009, 338, b158.
[http://dx.doi.org/10.1136/bmj.b158] [PMID: 19196745]

Guarino, A.; Favieri, F.; Boncompagni, I.; Agostini, F.; Cantone, M.; Casagrande, M. Executive functions in Alzheimer disease: A systematic review. Front. Aging Neurosci., 2019, 10, 437.
[http://dx.doi.org/10.3389/fnagi.2018.00437] [PMID: 30697157]

Cooper, C.; Katona, C.; Orrell, M.; Livingston, G. Coping strategies, anxiety and depression in caregivers of people with Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 2008, 23(9), 929-936.
[http://dx.doi.org/10.1002/gps.2007] [PMID: 18383189]

Ferretti, L.; McCurry, S.M.; Logsdon, R.; Gibbons, L.; Teri, L. Anxiety and Alzheimer’s disease. J. Geriatr. Psychiatry Neurol., 2001, 14(1), 52-58.
[http://dx.doi.org/10.1177/089198870101400111] [PMID: 11281317]

Garcez, M.L.; Falchetti, A.C.B.; Mina, F.; Budni, J. Alzheimer’s disease associated with psychiatric comorbidities. An. Acad. Bras. Cienc., 2015, 87(2), 1461-1473.
[http://dx.doi.org/10.1590/0001-3765201520140716] [PMID: 26312426]

Du, X.; Wang, X.; Geng, M. Alzheimer’s disease hypothesis and related therapies. Transl. Neurodegener., 2018, 7, 2.
[http://dx.doi.org/10.1186/s40035-018-0107-y] [PMID: 29423193]

Mohandas, E.; Rajmohan, V.; Raghunath, B. Neurobiology of Alzheimer’s disease. Indian J. Psychiatry, 2009, 51(1), 55-61.
[http://dx.doi.org/10.4103/0019-5545.44908] [PMID: 19742193]

Amakiri, N.; Kubosumi, A.; Tran, J.; Reddy, P.H. Amyloid beta and microRNAs in alzheimer’s disease. Front. Neurosci., 2019, 13(430), 430.
[http://dx.doi.org/10.3389/fnins.2019.00430] [PMID: 31130840]

Lee, H.G.; Zhu, X.; Nunomura, A.; Perry, G.; Smith, M.A. Amyloid beta: The alternate hypothesis. Curr. Alzheimer Res., 2006, 3(1), 75-80.
[http://dx.doi.org/10.2174/156720506775697124] [PMID: 16472207]

Gralle, M.; Ferreira, S.T. Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. Prog. Neurobiol., 2007, 82(1), 11-32.
[http://dx.doi.org/10.1016/j.pneurobio.2007.02.001] [PMID: 17428603]

O’Brien, R.J.; Wong, P.C. Amyloid precursor protein processing and Alzheimer’s disease. Annu. Rev. Neurosci., 2011, 34, 185-204.
[http://dx.doi.org/10.1146/annurev-neuro-061010-113613] [PMID: 21456963]

Murphy, M.P.; LeVine, H., III Alzheimer’s disease and the amyloid-beta peptide. J. Alzheimers Dis., 2010, 19(1), 311-323.
[http://dx.doi.org/10.3233/JAD-2010-1221] [PMID: 20061647]

Masters, C.L.; Selkoe, D.J. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med., 2012, 2(6), a006262.
[http://dx.doi.org/10.1101/cshperspect.a006262] [PMID: 22675658]

Bartus, R. T.; Dean, R. L., 3rd; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science (80-. ), 1982, 217(4558), 408-414.
[http://dx.doi.org/10.1126/science.7046051]

Colović, M.B.; Krstić, D.Z.; Lazarević-Pašti, T.D.; Bondžić, A.M.; Vasić, V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr. Neuropharmacol., 2013, 11(3), 315-335.
[http://dx.doi.org/10.2174/1570159X11311030006] [PMID: 24179466]

Tumiatti, V.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Milelli, A.; Matera, R.; Melchiorre, C. Progress in acetylcholinesterase inhibitors for Alzheimer’s disease: An update. Expert Opin. Ther. Pat., 2008, 18(4), 387-401.
[http://dx.doi.org/10.1517/13543776.18.4.387]

Saify, Z.S.; Sultana, N. Chapter 7- Role of acetylcholinesterase inhibitors and alzheimer disease.In: Drug Design and Discovery in Alzheimer’s Disease; Atta ur, R; Choudhary, M.I., Ed.; Elsevier, 2014, pp. 387-425.

Deirram, N.; Zhang, C.; Kermaniyan, S.S.; Johnston, A.P.R.; Such, G.K. pH-responsive polymer nanoparticles for drug delivery. Macromol. Rapid Commun., 2019, 40(10), e1800917.
[http://dx.doi.org/10.1002/marc.201800917] [PMID: 30835923]

Castro, K. C. ; de, ; Costa, J. M.; Campos, M. G. N. DrugLoaded polymeric nanoparticles: A review. Int. J. Poly. Mater. Poly. Biomat., 2020.
[http://dx.doi.org/10.1080/00914037.2020.1798436]

Dhas, N.; Mehta, T. Cationic biopolymer functionalized nanoparticles encapsulating lutein to attenuate oxidative stress in effective treatment of Alzheimer’s disease: A non-invasive approach. Int. J. Pharm., 2020, 586, 119553.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119553] [PMID: 32561306]

Beddoes, C.M.; Case, C.P.; Briscoe, W.H. Understanding nanoparticle cellular entry: A physicochemical perspective. Adv. Colloid Interface Sci., 2015, 218, 48-68.
[http://dx.doi.org/10.1016/j.cis.2015.01.007] [PMID: 25708746]

Kou, L.; Sun, J.; Zhai, Y.; He, Z. The endocytosis and intracellular fate of nanomedicines: Implication for rational design. Asian J. Pharm. Sci., 2013, 8(1), 10.

Del Prado-Audelo, M.L.; Caballero-Florán, I.H.; Sharifi-Rad, J.; Mendoza-Muñoz, N.; González-Torres, M.; Urbán-Morlán, Z.; Florán, B.; Cortes, H.; Leyva-Gómez, G. Chitosan-decorated nanoparticles for drug delivery. J. Drug Deliv. Sci. Technol., 2020, 59, 101896.
[http://dx.doi.org/10.1016/j.jddst.2020.101896]

Sunena; Singh, S.K.; Mishra, D.N. Nose to brain delivery of galantamine loaded nanoparticles: In vivo pharmacodynamic and biochemical study in mice. Curr. Drug Deliv., 2019, 16(1), 51-58.
[http://dx.doi.org/10.2174/1567201815666181004094707] [PMID: 30289074]

Hanafy, A.S.; Farid, R.M.; Helmy, M.W.; ElGamal, S.S. Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: Future potential contribution in Alzheimer’s disease management. Drug Deliv., 2016, 23(8), 3111-3122.
[http://dx.doi.org/10.3109/10717544.2016.1153748] [PMID: 26942549]

Hanafy, A.S.; Farid, R.M.; ElGamal, S.S. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer’s disease management: Preparation and detection in rat brain. Drug Dev. Ind. Pharm., 2015, 41(12), 2055-2068.
[http://dx.doi.org/10.3109/03639045.2015.1062897] [PMID: 26133084]

McNeela, E.A.; O’Connor, D.; Jabbal-Gill, I.; Illum, L.; Davis, S.S.; Pizza, M.; Peppoloni, S.; Rappuoli, R.; Mills, K.H. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine, 2000, 19(9-10), 1188-1198.
[http://dx.doi.org/10.1016/S0264-410X(00)00309-1] [PMID: 11137256]

Alves, S.; Churlaud, G.; Audrain, M.; Michaelsen-Preusse, K.; Fol, R.; Souchet, B.; Braudeau, J.; Korte, M.; Klatzmann, D.; Cartier, N. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice. Brain, 2017, 140(3), 826-842.
[http://dx.doi.org/10.1093/brain/aww330] [PMID: 28003243]

Heydari, S.; Hedayati, Ch.M.; Saadat, F.; Abedinzade, M.; Nikokar, I.; Aboutaleb, E.; Khafri, A.; Mokarram, A.R. Diphtheria toxoid nanoparticles improve learning and memory impairment in animal model of Alzheimer’s disease. Pharmacol. Rep., 2020, 72(4), 814-826.
[http://dx.doi.org/10.1007/s43440-019-00017-w] [PMID: 32048245]

Zameer, S.; Ali, J.; Vohora, D.; Najmi, A.K.; Akhtar, M. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against alzheimer’s disease in Intracerebroventricular streptozotocin model for brain delivery. J. Drug Target., 2021, 29(2), 199-216.
[http://dx.doi.org/10.1080/1061186X.2020.1817041] [PMID: 32876502]

Cardia, M.C.; Carta, A.R.; Caboni, P.; Maccioni, A.M.; Erbì, S.; Boi, L.; Meloni, M.C.; Lai, F.; Sinico, C. Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders. Pharmaceutics, 2019, 11(12), 657.
[http://dx.doi.org/10.3390/pharmaceutics11120657] [PMID: 31817711]

Shamarekh, K.S.; Gad, H.A.; Soliman, M.E.; Sammour, O.A. Development and evaluation of protamine-coated PLGA nanoparticles for nose-to-brain delivery of tacrine: In vitro and in vivo Assessment. J. Drug Deliv. Sci. Technol., 2020, 57, 101724.
[http://dx.doi.org/10.1016/j.jddst.2020.101724]

Wong, L.R.; Ho, P.C. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer’s disease. J. Pharm. Pharmacol., 2018, 70(1), 59-69.
[http://dx.doi.org/10.1111/jphp.12836] [PMID: 29034965]

Liu, Q.; Zhang, Q. 10 - nanoparticle systems for nose-to-brain delivery.In: Brain Targeted Drug Delivery System; Gao, H.; Gao, X., Eds.; Academic Press, 2019, pp. 219-239.
[http://dx.doi.org/10.1016/B978-0-12-814001-7.00010-X]

Shen, Y.; Chen, J.; Liu, Q.; Feng, C.; Gao, X.; Wang, L.; Zhang, Q.; Jiang, X. Effect of wheat germ agglutinin density on cellular uptake and toxicity of wheat germ agglutinin conjugated PEG-PLA nanoparticles in Calu-3 cells. Int. J. Pharm., 2011, 413(1-2), 184-193.
[http://dx.doi.org/10.1016/j.ijpharm.2011.04.026] [PMID: 21550388]

Su, Y.; Sun, B.; Gao, X.; Dong, X.; Fu, L.; Zhang, Y.; Li, Z.; Wang, Y.; Jiang, H.; Han, B. Intranasal delivery of targeted nanoparticles loaded with miR-132 to brain for the treatment of neurodegenerative diseases. Front. Pharmacol., 2020, 11, 1165.
[http://dx.doi.org/10.3389/fphar.2020.01165] [PMID: 32848773]

Meng, Q.; Wang, A.; Hua, H.; Jiang, Y.; Wang, Y.; Mu, H.; Wu, Z.; Sun, K. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. Int. J. Nanomedicine, 2018, 13, 705-718.
[http://dx.doi.org/10.2147/IJN.S151474] [PMID: 29440896]

Muntimadugu, E.; Dhommati, R.; Jain, A.; Challa, V.G.S.; Shaheen, M.; Khan, W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer’s disease. Eur. J. Pharm. Sci., 2016, 92, 224-234.
[http://dx.doi.org/10.1016/j.ejps.2016.05.012] [PMID: 27185298]

Al Harthi, S.; Alavi, S.E.; Radwan, M.A.; El Khatib, M.M.; AlSarra, I.A. Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer’s disease. Sci. Rep., 2019, 9(1), 9563.
[http://dx.doi.org/10.1038/s41598-019-46032-y] [PMID: 31266990]

Nageeb El-Helaly, S.; Abd Elbary, A.; Kassem, M.A.; El-Nabarawi, M.A. Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: Preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. Drug Deliv., 2017, 24(1), 692-700.
[http://dx.doi.org/10.1080/10717544.2017.1309476] [PMID: 28415883]

Al Asmari, A.K.; Ullah, Z.; Tariq, M.; Fatani, A. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des. Devel. Ther., 2016, 10, 205-215.
[http://dx.doi.org/10.2147/DDDT.S93937] [PMID: 26834457]

Sibinovska, N.; Žakelj, S.; Roškar, R.; Kristan, K. Suitability and functional characterization of two Calu-3 cell models for prediction of drug permeability across the airway epithelial barrier. Int. J. Pharm., 2020, 585, 119484.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119484] [PMID: 32485216]

Witschi, C.; Mrsny, R.J. In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery. Pharm. Res., 1999, 16(3), 382-390.
[http://dx.doi.org/10.1023/A:1018869601502] [PMID: 10213368]

Furubayashi, T.; Inoue, D.; Nishiyama, N.; Tanaka, A.; Yutani, R.; Kimura, S.; Katsumi, H.; Yamamoto, A.; Sakane, T. Comparison of various cell lines and three-dimensional mucociliary tissue model systems to estimate drug permeability using an in vitro transport study to predict nasal drug absorption in rats. Pharmaceutics, 2020, 12(1), 79.
[http://dx.doi.org/10.3390/pharmaceutics12010079] [PMID: 31963555]

Inoue, D.; Furubayashi, T.; Tanaka, A.; Sakane, T.; Sugano, K. Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats. Eur. J. Pharm. Biopharm., 2020, 149, 145-153.
[http://dx.doi.org/10.1016/j.ejpb.2020.02.004] [PMID: 32057906]

Zhang, L.; Du, S-Y.; Lu, Y.; Liu, C.; Tian, Z-H.; Yang, C.; Wu, H-C.; Wang, Z. Puerarin transport across a Calu-3 cell monolayer - an in vitro model of nasal mucosa permeability and the influence of paeoniflorin and menthol. Drug Des. Devel. Ther., 2016, 10, 2227-2237.
[http://dx.doi.org/10.2147/DDDT.S110247] [PMID: 27468226]

Zheng, X.; Shao, X.; Zhang, C.; Tan, Y.; Liu, Q.; Wan, X.; Zhang, Q.; Xu, S.; Jiang, X. Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer’s disease. Pharm. Res., 2015, 32(12), 3837-3849.
[http://dx.doi.org/10.1007/s11095-015-1744-9] [PMID: 26113236]

Katdare, A.; Khunt, D.; Thakkar, S.; Polaka, S.N.; Misra, M. Comparative evaluation of fish oil and butter oil in modulating delivery of galantamine hydrobromide to brain via intranasal route: Pharmacokinetic and oxidative stress studies. Drug Deliv. Transl. Res., 2020, 10(4), 1136-1146.
[http://dx.doi.org/10.1007/s13346-020-00739-y] [PMID: 32219727]

Shah, B.; Khunt, D.; Misra, M.; Padh, H. Formulation and in vivo pharmacokinetic consideration of intranasal microemulsion and mucoadhesive microemulsion of rivastigmine for brain targeting. Pharm. Res., 2018, 35(1), 8.
[http://dx.doi.org/10.1007/s11095-017-2279-z] [PMID: 29294189]

Sharma, D.; Singh, M.; Kumar, P.; Vikram, V.; Mishra, N. Development and characterization of morin hydrate loaded microemulsion for the management of Alzheimer’s disease. Artif. Cells Nanomed. Biotechnol., 2017, 45(8), 1620-1630.
[http://dx.doi.org/10.1080/21691401.2016.1276919] [PMID: 28102083]

Kaur, A.; Nigam, K.; Srivastava, S.; Tyagi, A.; Dang, S. Memantine nanoemulsion: A new approach to treat Alzheimer’s disease. J. Microencapsul., 2020, 37(5), 355-365.
[http://dx.doi.org/10.1080/02652048.2020.1756971] [PMID: 32293915]

Gupta, A.; Eral, H.B.; Hatton, T.A.; Doyle, P.S. Nanoemulsions: Formation, properties and applications. Soft Matter, 2016, 12(11), 2826-2841.
[http://dx.doi.org/10.1039/C5SM02958A] [PMID: 26924445]

McClements, D.J. Nanoemulsions versus microemulsions: Terminology, differences, and similarities. Soft Matter, 2012, 8(6), 1719-1729.
[http://dx.doi.org/10.1039/C2SM06903B]

Casadomé-Perales, Á.; Matteis, L.; Alleva, M.; Infantes-Rodríguez, C.; Palomares-Pérez, I.; Saito, T.; Saido, T.C.; Esteban, J.A.; Nebreda, A.R.; de la Fuente, J.M.; Dotti, C.G. Inhibition of p38 MAPK in the brain through nasal administration of p38 inhibitor loaded in chitosan nanocapsules. Nanomedicine (Lond.), 2019, 14(18), 2409-2422.
[http://dx.doi.org/10.2217/nnm-2018-0496] [PMID: 31456488]

Kaur, A.; Nigam, K.; Bhatnagar, I.; Sukhpal, H.; Awasthy, S.; Shankar, S.; Tyagi, A.; Dang, S. Treatment of Alzheimer’s diseases using donepezil nanoemulsion: An intranasal approach. Drug Deliv. Transl. Res., 2020, 10(6), 1862-1875.
[http://dx.doi.org/10.1007/s13346-020-00754-z] [PMID: 32297166]

Jiang, Y.; Liu, C.; Zhai, W.; Zhuang, N.; Han, T.; Ding, Z. The optimization design of lactoferrin loaded HupA nanoemulsion for targeted drug transport via intranasal route. Int. J. Nanomedicine, 2019, 14, 9217-9234.
[http://dx.doi.org/10.2147/IJN.S214657] [PMID: 31819426]

Rajput, A.; Bariya, A.; Allam, A.; Othman, S.; Butani, S.B. In situ nanostructured hydrogel of resveratrol for brain targeting: In vitro in vivo characterization. Drug Deliv. Transl. Res., 2018, 8(5), 1460-1470.
[http://dx.doi.org/10.1007/s13346-018-0540-6] [PMID: 29785574]

Ceulemans, J.; Vinckier, I.; Ludwig, A. The use of xanthan gum in an ophthalmic liquid dosage form: Rheological characterization of the interaction with mucin. J. Pharm. Sci., 2002, 91(4), 1117-1127.
[http://dx.doi.org/10.1002/jps.10106] [PMID: 11948550]

de Oliveira Cardoso, V.M.; Gremião, M.P.D.; Cury, B.S.F. Mucin-polysaccharide interactions: A rheological approach to evaluate the effect of pH on the mucoadhesive properties. Int. J. Biol. Macromol., 2020, 149, 234-245.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.01.235] [PMID: 31982533]

Mahdi, M.H.; Conway, B.R.; Smith, A.M. Development of mucoadhesive sprayable gellan gum fluid gels. Int. J. Pharm., 2015, 488(1-2), 12-19.
[http://dx.doi.org/10.1016/j.ijpharm.2015.04.011] [PMID: 25863119]

Menchicchi, B.; Fuenzalida, J.P.; Hensel, A.; Swamy, M.J.; David, L.; Rochas, C.; Goycoolea, F.M. Biophysical analysis of the molecular interactions between polysaccharides and mucin. Biomacromolecules, 2015, 16(3), 924-935.
[http://dx.doi.org/10.1021/bm501832y] [PMID: 25630032]

Osmałek, T.Z.; Froelich, A.; Jadach, B.; Krakowski, M. Rheological investigation of high-acyl gellan gum hydrogel and its mixtures with simulated body fluids. J. Biomater. Appl., 2018, 32(10), 1435-1449.
[http://dx.doi.org/10.1177/0885328218762361] [PMID: 29534627]

Ham, T.J.; Nollen, E.A.A. Caenorhabditis elegans as a model organism for dementia.In: Animal Models of Dementia , 2011; pp. 241-253.
[http://dx.doi.org/10.1007/978-1-60761-898-0_13]

Van Pelt, K.M.; Truttmann, M.C. Caenorhabditis elegans as a model system for studying aging-associated neurodegenerative diseases. Transl. Med. Aging, 2020, 4, 60-72.
[http://dx.doi.org/10.1016/j.tma.2020.05.001]

Alexander, A.G.; Marfil, V.; Li, C. Use of Caenorhabditis elegans as a model to study Alzheimer’s disease and other neurodegenerative diseases. Front. Genet., 2014, 5, 279.
[http://dx.doi.org/10.3389/fgene.2014.00279] [PMID: 25250042]

Wang, Y.A.; Kammenga, J.E.; Harvey, S.C. Genetic variation in neurodegenerative diseases and its accessibility in the model organism Caenorhabditis elegans. Hum. Genomics, 2017, 11(1), 12.
[http://dx.doi.org/10.1186/s40246-017-0108-4] [PMID: 28545550]

Anand, A.; Arya, M.; Kaithwas, G.; Singh, G.; Saraf, S.A. Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. Elegans Model. J. Drug Deliv. Sci. Technol., 2019, 49, 219-226.
[http://dx.doi.org/10.1016/j.jddst.2018.11.021]

Poewe, W.; Seppi, K.; Tanner, C.M.; Halliday, G.M.; Brundin, P.; Volkmann, J.; Schrag, A-E.; Lang, A.E. Parkinson disease. Nat. Rev. Dis. Primers, 2017, 3(1), 17013.
[http://dx.doi.org/10.1038/nrdp.2017.13] [PMID: 28332488]

Clarke, C.E. Parkinson’s disease. BMJ, 2007, 335(7617), 441-445.
[http://dx.doi.org/10.1136/bmj.39289.437454.AD] [PMID: 17762036]

Heijmans, M.; Habets, J.G.V.; Herff, C.; Aarts, J.; Stevens, A.; Kuijf, M.L.; Kubben, P.L. Monitoring Parkinson’s disease symptoms during daily life: A feasibility study. NPJ Parkinsons Dis., 2019, 5(1), 21.
[http://dx.doi.org/10.1038/s41531-019-0093-5] [PMID: 31583270]

Barnes, J.; David, A.S. Visual hallucinations in Parkinson’s disease: A review and phenomenological survey. J. Neurol. Neurosurg. Psychiatry, 2001, 70(6), 727-733.
[http://dx.doi.org/10.1136/jnnp.70.6.727] [PMID: 11385004]

Fénelon, G.; Mahieux, F.; Huon, R.; Ziégler, M. Hallucinations in Parkinson’s disease: Prevalence, phenomenology and risk factors. Brain, 2000, 123(Pt 4), 733-745.
[http://dx.doi.org/10.1093/brain/123.4.733] [PMID: 10734005]

Holroyd, S.; Currie, L.; Wooten, G.F. Prospective study of hallucinations and delusions in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 2001, 70(6), 734-738.
[http://dx.doi.org/10.1136/jnnp.70.6.734] [PMID: 11385005]

Aarsland, D.; Brønnick, K.; Ehrt, U.; De Deyn, P.P.; Tekin, S.; Emre, M.; Cummings, J.L. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: Frequency, profile and associated care giver stress. J. Neurol. Neurosurg. Psychiatry, 2007, 78(1), 36-42.
[http://dx.doi.org/10.1136/jnnp.2005.083113] [PMID: 16820421]

Jankovic, J. Parkinson’s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. & Psychiatry, 2008, 79(4), 368.
[http://dx.doi.org/10.1136/jnnp.2007.131045]

De Pablo-Fernandez, E.; Tur, C.; Revesz, T.; Lees, A.J.; Holton, J.L.; Warner, T.T. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol., 2017, 74(8), 970-976.
[http://dx.doi.org/10.1001/jamaneurol.2017.1125] [PMID: 28655059]

Gomperts, S.N. Lewy body dementias: Dementia with lewy bodies and parkinson disease dementia. Continuum (Minneap. Minn)., 2016, 22(2), 435-463.
[http://dx.doi.org/10.1212/CON.0000000000000309]

Outeiro, T.F.; Koss, D.J.; Erskine, D.; Walker, L.; Kurzawa-Akanbi, M.; Burn, D.; Donaghy, P.; Morris, C.; Taylor, J-P.; Thomas, A.; Attems, J.; McKeith, I. Dementia with lewy bodies: An update and outlook. Mol. Neurodegener., 2019, 14(1), 5.
[http://dx.doi.org/10.1186/s13024-019-0306-8] [PMID: 30665447]

Vaillancourt, D.E.; Mitchell, T. Parkinson’s disease progression in the substantia nigra: Location, location, location. Brain, 2020, 143(9), 2628-2630.
[http://dx.doi.org/10.1093/brain/awaa252] [PMID: 32947614]

Cheong, S.L.; Federico, S.; Spalluto, G.; Klotz, K-N.; Pastorin, G. The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy. Drug Discov. Today, 2019, 24(9), 1769-1783.
[http://dx.doi.org/10.1016/j.drudis.2019.05.003] [PMID: 31102728]

Levodopa and the progression of parkinson’s disease. N. Engl. J. Med., 2004, 351(24), 2498-2508.
[http://dx.doi.org/10.1056/NEJMoa033447] [PMID: 15590952]

Dhall, R.; Kreitzman, D.L. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology, 2016, 86(14)(Suppl. 1), S13-S24.
[http://dx.doi.org/10.1212/WNL.0000000000002510] [PMID: 27044646]

Dezsi, L.; Vecsei, L. Monoamine oxidase B inhibitors in parkinson’s disease. CNS Neurol. Disord. Drug Targets, 2017, 16(4), 425-439.
[http://dx.doi.org/10.2174/1871527316666170124165222] [PMID: 28124620]

Konta, B.; Frank, W. The treatment of Parkinson’s disease with dopamine agonists. GMS Health Technol. Assess., 2008, 4, Doc05-Doc05.
[PMID: 21289911]

Müller, T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs, 2015, 75(2), 157-174.
[http://dx.doi.org/10.1007/s40265-014-0343-0] [PMID: 25559423]

Holloway, R.; Frank, S. Review: Anticholinergic drugs improve motor function and disability in parkinson disease. ACP J. Club, 2004, 140(1), 15.

Katzenschlager, R.; Sampaio, C.; Costa, J.; Lees, A. Anticholinergics for symptomatic management of parkinson’s disease. Cochrane Database Syst. Rev., 2002, (3)
[http://dx.doi.org/10.1002/14651858.CD003735] [PMID: 12804486]

Meredith, G.E.; Rademacher, D.J. MPTP mouse models of Parkinson’s disease: An update. J. Parkinsons Dis., 2011, 1(1), 19-33.
[http://dx.doi.org/10.3233/JPD-2011-11023] [PMID: 23275799]

Arisoy, S.; Sayiner, O.; Comoglu, T.; Onal, D.; Atalay, O.; Pehlivanoglu, B. In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. Pharm. Dev. Technol., 2020, 25(6), 735-747.
[http://dx.doi.org/10.1080/10837450.2020.1740257] [PMID: 32141798]

Tang, S.; Wang, A.; Yan, X.; Chu, L.; Yang, X.; Song, Y.; Sun, K.; Yu, X.; Liu, R.; Wu, Z.; Xue, P. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease. Drug Deliv., 2019, 26(1), 700-707.
[http://dx.doi.org/10.1080/10717544.2019.1636420] [PMID: 31290705]

Bi, C.; Wang, A.; Chu, Y.; Liu, S.; Mu, H.; Liu, W.; Wu, Z.; Sun, K.; Li, Y. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment. Int. J. Nanomedicine, 2016, 11, 6547-6559.
[http://dx.doi.org/10.2147/IJN.S120939] [PMID: 27994458]

Raj, R.; Wairkar, S.; Sridhar, V.; Gaud, R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int. J. Biol. Macromol., 2018, 109, 27-35.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.12.056] [PMID: 29247729]

Mittal, D.; Md, S.; Hasan, Q.; Fazil, M.; Ali, A.; Baboota, S.; Ali, J. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv., 2016, 23(1), 130-139.
[http://dx.doi.org/10.3109/10717544.2014.907372] [PMID: 24786489]

Lu, C.T.; Jin, R.R.; Jiang, Y.N.; Lin, Q.; Yu, W.Z.; Mao, K.L.; Tian, F.R.; Zhao, Y.P.; Zhao, Y.Z. Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: An in vitro and in vivo study. Drug Des. Devel. Ther., 2015, 9, 1955-1962.
[http://dx.doi.org/10.2147/DDDT.S77237] [PMID: 25897205]

Wei, H.; Liu, T.; Jiang, N.; Zhou, K.; Yang, K.; Ning, W.; Yu, Y. A novel delivery system of cyclovirobuxine d for brain targeting: Angiopep-conjugated polysorbate 80-coated liposomes via intranasal administration. J. Biomed. Nanotechnol., 2018, 14(7), 1252-1262.
[http://dx.doi.org/10.1166/jbn.2018.2581] [PMID: 29944099]

Das Mandal, S.; Mandal, S.; Patel, J. Intranasal mucoadhesivemicroemulsion for neuroprotective effect of curcuminin Mptp induced Parkinson model. Braz. J. Pharm. Sci., 2017, 53.
[http://dx.doi.org/10.1590/s2175-97902017000215223]

Pardeshi, C.V.; Belgamwar, V.S.N. N N,N-trimethyl chitosan modified flaxseed oil based mucoadhesive neuronanoemulsions for direct nose to brain drug delivery. Int. J. Biol. Macromol., 2018, 120(Pt B), 2560-2571.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.09.032] [PMID: 30201564]

Mandal, S.; Das Mandal, S.; Chuttani, K.; Sawant, K.K.; Subudhi, B.B. Neuroprotective effect of ibuprofen by intranasal application of mucoadhesive nanoemulsion in MPTP induced parkinson model. J. Pharm. Investig., 2016, 46(1), 41-53.
[http://dx.doi.org/10.1007/s40005-015-0212-1]

de Oliveira, Junior E.R.; Truzzi, E.; Ferraro, L.; Fogagnolo, M.; Pavan, B.; Beggiato, S.; Rustichelli, C.; Maretti, E.; Lima, E.M.; Leo, E.; Dalpiaz, A. Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson’s disease. J. Control. Release, 2020, 321, 540-552.
[http://dx.doi.org/10.1016/j.jconrel.2020.02.033] [PMID: 32092370]

Pardeshi, C.V.; Belgamwar, V.S. Improved brain pharmacokinetics following intranasal administration of N,N,N-trimethyl chitosan tailored mucoadhesive NLCs. Mater. Technol., 2020, 35(5), 249-266.
[http://dx.doi.org/10.1080/10667857.2019.1674522]

Hernando, S.; Herran, E.; Figueiro-Silva, J.; Pedraz, J.L.; Igartua, M.; Carro, E.; Hernandez, R.M. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease. Mol. Neurobiol., 2018, 55(1), 145-155.
[http://dx.doi.org/10.1007/s12035-017-0728-7] [PMID: 28866799]

Gartziandia, O.; Herrán, E.; Ruiz-Ortega, J.A.; Miguelez, C.; Igartua, M.; Lafuente, J.V.; Pedraz, J.L.; Ugedo, L.; Hernández, R.M. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson’s disease. J. Biomed. Nanotechnol., 2016, 12(12), 2220-2230.
[http://dx.doi.org/10.1166/jbn.2016.2313] [PMID: 29372975]

Daubner, S.C.; Le, T.; Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys., 2011, 508(1), 1-12.
[http://dx.doi.org/10.1016/j.abb.2010.12.017] [PMID: 21176768]

Chen, Y.; Fan, H.; Xu, C.; Hu, W.; Yu, B. Efficient cholera toxin B subunit-based nanoparticles with MRI capability for drug delivery to the brain following intranasal administration. Macromol. Biosci., 2019, 19(2), e1800340.
[http://dx.doi.org/10.1002/mabi.201800340] [PMID: 30536989]

World Health Organization. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescent, 2018.

Li, J.; Zhao, J.; Tan, T.; Liu, M.; Zeng, Z.; Zeng, Y.; Zhang, L.; Fu, C.; Chen, D.; Xie, T. Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review. Int. J. Nanomedicine, 2020, 15, 2563-2582.
[http://dx.doi.org/10.2147/IJN.S243223] [PMID: 32368041]

International agency for research on cancer. Global cancer observatory (GLOBOCAN)..

Filbin, M.G.; Stiles, C.D. of brains and blood: Developmental origins of glioma diversity? Cancer Cell, 2015, 28(4), 403-404.
[http://dx.doi.org/10.1016/j.ccell.2015.09.013] [PMID: 26461085]

Geldenhuys, W.; Mbimba, T.; Bui, T.; Harrison, K.; Sutariya, V. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J. Drug Target., 2011, 19(9), 837-845.
[http://dx.doi.org/10.3109/1061186X.2011.589435] [PMID: 21692650]

Ferreira, N.N.; Granja, S.; Boni, F.I.; Prezotti, F.G.; Ferreira, L.M.B.; Cury, B.S.F.; Reis, R.M.; Baltazar, F.; Gremião, M.P.D. Modulating chitosan-PLGA nanoparticle properties to design a co-delivery platform for glioblastoma therapy intended for nose-to-brain route. Drug Deliv. Transl. Res., 2020, 10(6), 1729-1747.
[http://dx.doi.org/10.1007/s13346-020-00824-2] [PMID: 32683647]

Ullah, I.; Chung, K.; Bae, S.; Li, Y.; Kim, C.; Choi, B.; Nam, H.Y.; Kim, S.H.; Yun, C.O.; Lee, K.Y.; Kumar, P.; Lee, S.K. Nose-to-brain delivery of cancer-targeting paclitaxel-loaded nanoparticles potentiates antitumor effects in malignant glioblastoma. Mol. Pharm., 2020, 17(4), 1193-1204.
[http://dx.doi.org/10.1021/acs.molpharmaceut.9b01215] [PMID: 31944768]

de Oliveira, Junior E.R.; Nascimento, T.L.; Salomão, M.A.; da Silva, A.C.G.; Valadares, M.C.; Lima, E.M. Increased nose-to-brain delivery of melatonin mediated by polycaprolactone nanoparticles for the treatment of glioblastoma. Pharm. Res., 2019, 36(9), 131.
[http://dx.doi.org/10.1007/s11095-019-2662-z] [PMID: 31263962]

Sukumar, U.K.; Bose, R.J.C.; Malhotra, M.; Babikir, H.A.; Afjei, R.; Robinson, E.; Zeng, Y.; Chang, E.; Habte, F.; Sinclair, R.; Gambhir, S.S.; Massoud, T.F.; Paulmurugan, R. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials, 2019, 218, 119342.
[http://dx.doi.org/10.1016/j.biomaterials.2019.119342] [PMID: 31326657]

Chen, Y.S.; Chiu, Y.H.; Li, Y.S.; Lin, E.Y.; Hsieh, D.K.; Lee, C.H.; Huang, M.H.; Chuang, H.M.; Lin, S.Z.; Harn, H.J.; Chiou, T.W. Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors. Int. J. Nanomedicine, 2019, 14, 3601-3613.
[http://dx.doi.org/10.2147/IJN.S193617] [PMID: 31190814]

Chu, L.; Wang, A.; Ni, L.; Yan, X.; Song, Y.; Zhao, M.; Sun, K.; Mu, H.; Liu, S.; Wu, Z.; Zhang, C. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv., 2018, 25(1), 1634-1641.
[http://dx.doi.org/10.1080/10717544.2018.1494226] [PMID: 30176744]

Van Woensel, M.; Wauthoz, N.; Rosière, R.; Mathieu, V.; Kiss, R.; Lefranc, F.; Steelant, B.; Dilissen, E.; Van Gool, S.W.; Mathivet, T.; Gerhardt, H.; Amighi, K.; De Vleeschouwer, S. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J. Control. Release, 2016, 227, 71-81.
[http://dx.doi.org/10.1016/j.jconrel.2016.02.032] [PMID: 26902800]

Colombo, M.; Figueiró, F.; de Fraga Dias, A.; Teixeira, H.F.; Battastini, A.M.O.; Koester, L.S. Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. Int. J. Pharm., 2018, 543(1-2), 214-223.
[http://dx.doi.org/10.1016/j.ijpharm.2018.03.055] [PMID: 29605695]

Blatzer, M.; Lanternier, F.; Latgé, J-P.; Beauvais, A.; Bretagne, S.; Chrétien, F.; Jouvion, G. Fungal infections of the CNS.In: Infections of the Central Nervous System: Pathology and Genetics; Chrétien, F.; Wong, K.T.; Sharer, L.R., Eds.; Wiley Online Library, 2020, Vol. 1, pp. 419-436.
[http://dx.doi.org/10.1002/9781119467748.ch44]

Somand, D.; Meurer, W. Central nervous system infections. Emerg. Med. Clin. North Am., 2009, 27(1), 89-100. , ix.
[http://dx.doi.org/10.1016/j.emc.2008.07.00] [PMID: 19218021]

Giovane, R.A.; Lavender, P.D. Central nervous system infections. Pract., 2018, 45(3), 505-518.
[http://dx.doi.org/10.1016/j.pop.2018.05.007] [PMID: 30115337]

Nau, R.; Sörgel, F.; Eiffert, H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev., 2010, 23(4), 858-883.
[http://dx.doi.org/10.1128/CMR.00007-10] [PMID: 20930076]

Fowler, M.J.; Cotter, J.D.; Knight, B.E.; Sevick-Muraca, E.M.; Sandberg, D.I.; Sirianni, R.W. Intrathecal drug delivery in the era of nanomedicine. Adv. Drug Deliv. Rev., 2020, 165-166, 77-95.
[http://dx.doi.org/10.1016/j.addr.2020.02.006] [PMID: 32142739]

Manda, P.; Hargett, J.K.; Vaka, S.R.K.; Repka, M.A.; Murthy, S.N. Delivery of cefotaxime to the brain via intranasal administration. Drug Dev. Ind. Pharm., 2011, 37(11), 1306-1310.
[http://dx.doi.org/10.3109/03639045.2011.571696] [PMID: 21702731]

Eid, H.M.; Elkomy, M.H.; El Menshawe, S.F.; Salem, H.F. Transfersomal nanovesicles for nose-to-brain delivery of ofloxacin for better management of bacterial meningitis: formulation, optimization by box-behnken design, characterization and in vivo pharmacokinetic study. J. Drug Deliv. Sci. Technol., 2019, 54(July), 101304.
[http://dx.doi.org/10.1016/j.jddst.2019.101304]

Giuliani, A.; Balducci, A.G.; Zironi, E.; Colombo, G.; Bortolotti, F.; Lorenzini, L.; Galligioni, V.; Pagliuca, G.; Scagliarini, A.; Calzà, L.; Sonvico, F. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv., 2018, 25(1), 376-387.
[http://dx.doi.org/10.1080/10717544.2018.1428242] [PMID: 29382237]

Du, W.; Li, H.; Tian, B.; Sai, S.; Gao, Y.; Lan, T.; Meng, Y.; Ding, C. Development of nose-to-brain delivery of ketoconazole by nanostructured lipid carriers against cryptococcal meningoencephalitis in mice. Colloids Surf. B Biointerfaces, 2019, 183, 110446.
[http://dx.doi.org/10.1016/j.colsurfb.2019.110446] [PMID: 31465938]

Xia, F.; Kheirbek, M.A. Circuit-based biomarkers for mood and anxiety disorders. Trends Neurosci., 2020, 43(11), 902-915.
[http://dx.doi.org/10.1016/j.tins.2020.08.004] [PMID: 32917408]

Marvel, C.L.; Paradiso, S. Cognitive and neurological impairment in mood disorders. Psychiatr. Clin. North Am., 2004, 27(1), 19-36. vii-viii.
[http://dx.doi.org/10.1016/S0193-953X(03)00106-0] [PMID: 15062628]

Rakofsky, J.; Rapaport, M. Mood disorders. Continuum, 2018, 24(3), 804-827.
[http://dx.doi.org/10.1212/CON.0000000000000604] [PMID: 29851879]

Marneros, A. Mood disorders: Epidemiology and natural history. Psychiatry, 2009, 8(2), 52-55.
[http://dx.doi.org/10.1016/j.mppsy.2008.10.022]

Li, X.; Frye, M.A.; Shelton, R.C. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology, 2012, 37(1), 77-101.
[http://dx.doi.org/10.1038/npp.2011.198] [PMID: 21900884]

Penn, E.; Tracy, D.K. The drugs don’t work? antidepressants and the current and future pharmacological management of depression. Ther. Adv. Psychopharmacol., 2012, 2(5), 179-188.
[http://dx.doi.org/10.1177/2045125312445469] [PMID: 23983973]

Nemeroff, C.B.; Owens, M.J. Treatment of mood disorders. Nat. Neurosci., 2002, 5(S11), 1068-1070.
[http://dx.doi.org/10.1038/nn943] [PMID: 12403988]

O’Brien, F.E.; Dinan, T.G.; Griffin, B.T.; Cryan, J.F. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings. Br. J. Pharmacol., 2012, 165(2), 289-312.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01557.x] [PMID: 21718296]

Pires, P.C.; Santos, A.O. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J. Control. Release, 2018, 270(270), 89-100.
[http://dx.doi.org/10.1016/j.jconrel.2017.11.047] [PMID: 29199063]

Tavakoli, J.; Tang, Y. Hydrogel based sensors for biomedical applications: An updated review. Polymers (Basel), 2017, 9(8), 364.
[http://dx.doi.org/10.3390/polym9080364] [PMID: 30971040]

Wang, Q.S.; Li, K.; Gao, L.N.; Zhang, Y.; Lin, K.M.; Cui, Y.L. Intranasal delivery of berberine via in situ thermoresponsive hydrogels with non-invasive therapy exhibits better antidepressant-like effects. Biomater. Sci., 2020, 8(10), 2853-2865.
[http://dx.doi.org/10.1039/C9BM02006C] [PMID: 32270794]

Alam, M.I.; Baboota, S.; Ahuja, A.; Ali, M.; Ali, J.; Sahni, J.K.; Bhatnagar, A. Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. Int. J. Pharm., 2014, 470(1-2), 99-106.
[http://dx.doi.org/10.1016/j.ijpharm.2014.05.004] [PMID: 24810241]

El-Setouhy, D.A.; Ibrahim, A.B.; Amin, M.M.; Khowessah, O.M.; Elzanfaly, E.S. Intranasal haloperidol-loaded miniemulsions for brain targeting: Evaluation of locomotor suppression and in vivo biodistribution. Eur. J. Pharm. Sci., 2016, 92, 244-254.
[http://dx.doi.org/10.1016/j.ejps.2016.05.002] [PMID: 27154259]

Yasir, M.; Sara, U.V.S. Solid lipid nanoparticles for nose to brain delivery of haloperidol: In vitro drug release and pharmacokinetics evaluation. Acta Pharm. Sin. B, 2014, 4(6), 454-463.
[http://dx.doi.org/10.1016/j.apsb.2014.10.005] [PMID: 26579417]

Haque, S.; Md, S.; Sahni, J.K.; Ali, J.; Baboota, S. Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J. Psychiatr. Res., 2014, 48(1), 1-12.
[http://dx.doi.org/10.1016/j.jpsychires.2013.10.011] [PMID: 24231512]

Haque, S.; Md, S.; Fazil, M.; Kumar, M.; Sahni, J.K.; Ali, J.; Baboota, S. Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. Carbohydr. Polym., 2012, 89(1), 72-79.
[http://dx.doi.org/10.1016/j.carbpol.2012.02.051] [PMID: 24750606]

Xu, D.; Lu, Y.R.; Kou, N.; Hu, M.J.; Wang, Q.S.; Cui, Y.L. Intranasal delivery of icariin via a nanogel-thermoresponsive hydrogel compound system to improve its antidepressant-like activity. Int. J. Pharm., 2020, 586(January), 119550.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119550] [PMID: 32554031]

Kaur, P.; Garg, T.; Vaidya, B.; Prakash, A.; Rath, G.; Goyal, A.K. Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: behavioral and biochemical assessment. J. Drug Target., 2015, 23(3), 275-286.
[http://dx.doi.org/10.3109/1061186X.2014.994097] [PMID: 25539073]

Mittal, D.; Ali, A.; Md, S.; Baboota, S.; Sahni, J.K.; Ali, J. Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv., 2014, 21(2), 75-86.
[http://dx.doi.org/10.3109/10717544.2013.838713] [PMID: 24102636]

Vitorino, C.; Silva, S.; Bicker, J.; Falcão, A.; Fortuna, A. Antidepressants and nose-to-brain delivery: Drivers, restraints, opportunities and challenges. Drug Discov. Today, 2019, 24(9), 1911-1923.
[http://dx.doi.org/10.1016/j.drudis.2019.06.001] [PMID: 31181188]

Warnken, Z.N.; Smyth, H.D.C.; Watts, A.B.; Weitman, S.; Kuhn, J.G.; Williams, R.O. Formulation and device design to increase nose to brain drug delivery. J. Drug Deliv. Sci. Technol., 2016, 35, 213-222.
[http://dx.doi.org/10.1016/j.jddst.2016.05.003]

Alexander, A.; Agrawal, M.; Bhupal Chougule, M.; Saraf, S.; Saraf, S. Nose-to-brain drug delivery.In: Nanopharmaceuticals; Elsevier, 2020, pp. 175-200.
[http://dx.doi.org/10.1016/B978-0-12-817778-5.00009-9]

Farjadian, F.; Ghasemi, A.; Gohari, O.; Roointan, A.; Karimi, M.; Hamblin, M.R. Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities. Nanomedicine (Lond.), 2019, 14(1), 93-126.
[http://dx.doi.org/10.2217/nnm-2018-0120] [PMID: 30451076]

Nijhara, R.; Balakrishnan, K. Bringing nanomedicines to market: Regulatory challenges, opportunities, and uncertainties. Nanomedicine, 2006, 2(2), 127-136.
[http://dx.doi.org/10.1016/j.nano.2006.04.005] [PMID: 17292125]